Hyperkalemia in a Patient With Leukemia.

Am J Kidney Dis

Division of Nephrology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. Electronic address:

Published: May 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ajkd.2020.08.020DOI Listing

Publication Analysis

Top Keywords

hyperkalemia patient
4
patient leukemia
4
hyperkalemia
1
leukemia
1

Similar Publications

Hyperkalemia is a common and serious complication in dialysis patients, with increased incidence and severity over time. Newer potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), offer improved tolerability compared to older agents. This meta-analysis aims to evaluate the efficacy and safety of these newer binders in dialysis patients.

View Article and Find Full Text PDF

Purpose: End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and delay the progression of chronic kidney disease. We aim to perform a comprehensive analysis of current clinical evidence on the use of sacubitril/valsartan in ESRD patients.

View Article and Find Full Text PDF

Rationale: This case report aims to highlight a rare but life-threatening complication of femoral venous catheterization and to describe a novel endovascular technique for its management. Non-tunneled femoral catheters provide rapid vascular access for emergency dialysis (e.g.

View Article and Find Full Text PDF

Chikungunya virus (CHIKV) typically causes febrile illness and arthralgia. However, severe complications such as encephalitis, rhabdomyolysis, and multiorgan dysfunction are increasingly recognised, particularly during epidemics in endemic regions. We report a case of a 61-year old male presenting with progressive flaccid paraparesis and respiratory failure following febrile illness.

View Article and Find Full Text PDF

Background: Steroidal mineralocorticoid receptor antagonists (MRAs), including spironolactone, effectively treat resistant hypertension, reduce proteinuria and lower mortality in heart failure with reduced ejection fraction. However, their long-term effects in chronic kidney disease (CKD) remain unclear. This study investigated spironolactone's impact on end-stage renal disease (ESRD), major adverse cardiovascular events (MACE), hyperkalemia and mortality in CKD patients.

View Article and Find Full Text PDF